Sesen Bio Inc (SESN)

[Timing101]

Many that I know personally and past family with Bladder Cancer..
--
If one of these come through ... we are all better off
===
Press Release: Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial ReadoutsFont size: A | A | A
6:36 AM ET 11/8/18 | Dow Jones
RELATED QUOTES


10:44 AM ET 11/8/18
Symbol Last % Chg
SESN
1.78 15.35%
Real time quote.

Press Release: Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts



Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts

Company Expects to Report Six-Month Update from VISTA Trial in December 2018; On-Track to Report 12-Month VISTA Trial Data in Mid-2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 08, 2018--

Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today reported operating results for the third quarter ended September 30, 2018 and recent highlights from its development program for Vicinium(R) for patients with high-grade non-muscle invasive bladder cancer (NMIB